Mylan NV (NASDAQ:MYL)

38.73
Delayed Data
As of Sep 20
 +0.49 / +1.28%
Today’s Change
30.69
Today|||52-Week Range
47.82
-8.46%
Year-to-Date
Orbimed Advisors Llc Buys Tricida Inc, Anthem Inc, Allergan PLC, Sells Regeneron ...
Sep 20 / GuruFocus News - Paid Partner Content
Acorda Gets Unfavorable Court Ruling for Ampyra, Stock Down
Sep 11 / Zacks.com - Paid Partner Content
AbbVie Faces California Insurance Department Suit for Humira
Sep 19 / Zacks.com - Paid Partner Content
Glaxo's Nucala Suffers Regulatory Setback, Gets CRL for COPD
Sep 10 / Zacks.com - Paid Partner Content
Theravance, Mylan Report Positive Data on COPD Drug Yupelri
Sep 18 / Zacks.com - Paid Partner Content
New Strong Sell Stocks for September 10th
Sep 10 / Zacks.com - Paid Partner Content
Acorda (ACOR) Stock Dips, FDA Delays Decision on Inbrija
Sep 14 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close38.24
Today’s open38.36
Day’s range38.21 - 38.89
Volume3,251,954
Average volume (3 months)4,265,387
Market cap$20.0B
Data as of 4:00pm ET, 09/20/2018

Growth & Valuation

Earnings growth (last year)+41.30%
Earnings growth (this year)+2.79%
Earnings growth (next 5 years)+5.84%
Revenue growth (last year)+7.06%
P/E ratio45.0
Price/Sales1.91
Price/Book1.53

Competitors

 Today’s
change
Today’s
% change
BMRNBiomarin Pharmaceuti...+0.63+0.63%
INCYIncyte Corp+1.03+1.53%
SGENSeattle Genetics Inc+1.50+1.94%
ALXNAlexion Pharmaceutic...+2.64+2.16%
Data as of 4:00pm ET, 09/20/2018

Financials

Next reporting dateNovember 1, 2018
EPS forecast (this quarter)$1.22
Annual revenue (last year)$11.9B
Annual profit (last year)$696.0M
Net profit margin5.85%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
Chief Executive Officer &
Executive Director
Heather M. Bresch
President &
Executive Director
Rajiv Malik
Corporate headquarters
Hatfield, Hertfordshire

Forecasts